UPS - LEIDER IST IHR BROWSER VERALTET!

Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt.
Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:

arrowhead läuft - zu recht

Seite 1 von 15
neuester Beitrag: 12.06.19 11:00
eröffnet am: 14.02.05 11:14 von: brokeboy Anzahl Beiträge: 362
neuester Beitrag: 12.06.19 11:00 von: macos Leser gesamt: 68608
davon Heute: 46
bewertet mit 2 Sternen

Seite: Zurück 1 | 2 | 3 | 4 |
13 | 14 | 15 | 15  Weiter  

2590 Postings, 5252 Tage brokeboyarrowhead läuft - zu recht

 
  
    
2
14.02.05 11:14
...tja - da habe ich vorletzte Woche zwar einige skeptische Stimmen gehört ... und mittlerweile ging Arrowhead Research um 30%.
Hier noch einmal ein ganz interessanter Bericht über eine WIRKLICH CHANCENREICHE NANOAKTIE.

Arrowhead (deutsch "Pfeilspitze") Research trägt seinen Namen zu Recht: Ob es um die Neugründung einer Tochtergesellschaft oder die Beteiligung an aussichtsreichen Start-Ups geht - Arrowhead handelt schnell und zielsicher; vorausgesetzt, die jeweilige Technologie überzeugt, es existiert ein Prototyp sowie eine weitgehende Absicherung durch Patente. Laut einer Studie verfügt das Unternehmen mit 180 US- und internationalen Patenten über das weltweit am besten diversifizierte Patentportfolio im Nanotechnologie-Sektor. Zudem unterstützt man verschiedene Forschungsprogramme auf universitärer Ebene finanziell - im Gegenzug erhält Arrowhead die Vermarktungsrechte.

Finanzierung gesichert

Im Vergleich zu den für die einzelnen Projekte errechneten Marktvolumen (siehe Tabelle) ist das Unternehmen mit einer aktuellen Börsenbewertung von 54,8 Millionen Dollar unglaublich günstig zu haben. Bis 2008 muss Arrowhead für seine einzelnen Projekte jedoch rund 28 Millionen Dollar aufwenden, aktuell verfügt man über einen Cash-Bestand von 8,55 Millionen Dollar (Stand 30. September 2004). Eine Kapitalerhöhung dürfte daher unumgänglich sein. Arrowhead könnte aber auch ausstehende Optionsscheine einlösen, was dem Unternehmen rund 21 Millionen Dollar einbringen würde.

Fazit: Unglaublich günstig. Bei Arrowhead schlagen Anleger gleich mehrere Fliegen mit einer Klappe: Sie investieren in etliche aussichtsreiche Nanotechs und zugleich in unterschiedliche Branchen, die durch die Nanotechnologie maßgeblich beeinflusst werden. Die aktuelle Börsenbewertung zeigt nur einen Bruchteil des wahren Potenzials von Arrowhead. Allerdings müssen Anleger aufgrund der erwarteten Kapitalmaßnahmen mit einem volatilen Kurs rechnen.


Arrowhead - Gelungene Diversifikation

Produktvermarktung
durch drei Tochtergesellschaften

Anwendung
Marktpotenzial
(e) in Mio.$

Aonex
Halbleitermaterialien für Photovoltaik-Markt
75-100

Insert
Partikel für Medikamententransport
1.000

Nanotechnica
Nanoskalige Geräte und Sensoren
4.500

 

 
 

Forschungsprogramme
 
 

Nanoelektronik
Speicher- und Logik-Chips aus Kohlenstoff-Nanoröhren
75.000 (2014)

Nanobiologie
Diagnostik, Medikamentenforschung
6.000

Ferroelektrische Nanomaterialien
in Sensoren, Biochips, Düsen, Antennen, Kondensatoren
12.000

Quelle: Unternehmen; eigene Recherchen

Die "Pfeilspitze" der Nanotechnologie

Arrowhead

 

ISIN
US0427971009

Kurs am 25.01.2005
3,15 ?

Empfehlungskurs
3,25 ?

Ziel
6,50 ?

Stopp
2,50 ?

KGV 2005e
?

Chance/Risiko
5/5
 
Seite: Zurück 1 | 2 | 3 | 4 |
13 | 14 | 15 | 15  Weiter  
336 Postings ausgeblendet.

2122 Postings, 3915 Tage macosARO-AAT

 
  
    
16.04.19 11:53
Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
April 15, 2019 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20190415005133/en/

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company?s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

Arrowhead intends to initiate the adaptive design, Phase 2/3 study of ARO-AAT in patients with AATD associated liver disease at various sites in the U.S. in the second quarter of 2019, followed by various international sites in Europe, pending regulatory submission and review. The proposed primary objectives are to evaluate safety and pharmacodynamic dose response, and to evaluate efficacy, defined as an improvement in a histologic grading scale of AATD associated liver disease, and no worsening of liver fibrosis based on Ishak score on end of study biopsy. The company plans to provide additional study details following its initiation.  

2122 Postings, 3915 Tage macosPT Raised to $33

 
  
    
16.04.19 11:54
Arrowhead Research (ARWR) PT Raised to $33 at Piper Jaffray
April 15, 2019 4:58 PM EDT
https://www.streetinsider.com/Analyst+PT+Change/...fray/15372742.html  

2122 Postings, 3915 Tage macos#338

 
  
    
16.04.19 12:17
von Holden:YMB

Anyone who is looking for a differentiator in the RNAi space can stop here. This is the first company in the history of the world to receive such an approval. Whether or not Mr. Market gets it is irrelevant (It doesn't). EVERY BP will now have to play ball with ARWR for two simple reasons. 1) Superior proven delivery capability, and 2) The first and only FDA approved commercialization path that allows drugs to move through the clinic without interim filings.

This latter point is completely lost on the investment community. Think about it. ARWR can cruise through the clinic without two previously required filings. That reduces time to market with drugs by many months if not years. Time is money. This reduces commercialization costs by tens of millions for every ARWR drug. Tha's tens of millions that immediately flow to the pre-tax line.

ARO-AAT will be commercialized in 2020. This approval increases ARWR's lead on ALNY's ALN-AAT02 drug by a MINIMUM of a year. The lead now stands at at least 2 years. And every ARWR drug will have a least a year or two advantage over the competition. And what's the competition? Broadly looking at the landscape of companies that MIGHT have competitive delivery instruments it's ALNY and DRNA. And that's a BIG MIGHT. On these down market days it is tough to think about why the market isn't taking this announcement more seriously. Everyone is playing defense. But the value-creation engine at ARWR continues and with balance sheet issues off the table this stock is a generational good bet.
https://finance.yahoo.com/quote/ARWR/community?p=ARWR  

2122 Postings, 3915 Tage macosHBV

 
  
    
17.04.19 13:11
Inside Look: Janssen?s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Cornerstone
https://www.biospace.com/article/...-treatment-franchise-cornerstone/  

2122 Postings, 3915 Tage macosBürofläche in Pasadena vergrößert

 
  
    
23.04.19 12:54
On April 17, 2019, Arrowhead Pharmaceuticals, Inc. (?the Company?) entered into a new lease for its Pasadena, California corporate headquarters.  The 91month office building lease between the Company and 177 Colorado Owner, LLC is for approximately 24,000 square feet of office space located at 177 E.Colorado Blvd, Pasadena, California, and this lease will replace the Company?s current corporate headquarters office lease.  The increased capacity of thisnew office space compared to the Company?s current corporate headquarters will accommodate increased personnel as the Company?s pipeline of drugcandidates expands and moves closer to market.
http://ir.arrowheadpharma.com/static-files/...-4eed-955d-aeadaf223334
 

2122 Postings, 3915 Tage macosHBV

 
  
    
24.04.19 13:42
Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen
April 24, 2019 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20190424005179/en/
Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead, said: ?Both Arrowhead and Janssen share the aim to advance transformational medicines that achieve higher rates of functional cure with a finite treatment duration for patients with chronic hepatitis B viral infection. Beginning this new triple combination cohort in our ongoing AROHBV1001 study has the potential to generate valuable data rapidly.?  

2122 Postings, 3915 Tage macoswebcast and conference call on May 8. 2019

 
  
    
25.04.19 09:57
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 24, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2019 , at 4:30 p.m. EDT to discuss its financial results for the fiscal 2019 second quarter ended March 31, 2019 .
http://ir.arrowheadpharma.com/news-releases/...al-2019-second-quarter  

2122 Postings, 3915 Tage macosMay 2019 Conferences

 
  
    
02.05.19 13:43
Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences
May 02, 2019 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20190502005181/en/

Bank of America Merrill Lynch 2019 Health Care Conference ? Las Vegas, May 14-16, 2019

May 15, 8:40 a.m. PDT ? Christopher Anzalone, Ph.D., Arrowhead?s president and chief executive officer, will deliver a corporate presentation

Vascular Discovery: From Genes to Medicine 2019 Scientific Sessions (ATVB|PVD) ? Boston, May 14-16, 2019

May 15, 11:00 a.m. EDT ? So Wong, Ph.D., Arrowhead?s director of biology, will deliver a poster presentation titled, ?Reduction in Angiopoietin-Like Protein 3 via RNA Interference Improves Dyslipidemias and Hepatic Steatosis?

2019 National Lipid Association Scientific Sessions ? Aventura, FL, May 16-19, 2019

May 18, 11:25 a.m. EDT ? So Wong, Ph.D., Arrowhead?s director of biology, will deliver a poster presentation titled, ?Personalized Medicine for Dyslipidemias by RNA Interference-Mediated Reductions in Apolipoprotein C3 or Angiopoietin-Like Protein 3?

20th Annual B. Riley FBR Institutional Investor Conference ? Beverly Hills, May 22-23, 2019

May 23, 8:30 a.m. PDT ? Christopher Anzalone, Ph.D., Arrowhead?s president and chief executive officer, will participate in a fireside chat presentation with Mayank Mamtani, B. Riley FBR research analyst  

2122 Postings, 3915 Tage macossehr gute Quartalskonferenz

 
  
    
09.05.19 12:10
very bullisch :-)))

Edited Transcript of ARWR earnings conference call or presentation 8-May-19 8:30pm GMT
Thomson Reuters StreetEvents?May 9, 2019
https://finance.yahoo.com/news/...-earnings-conference-075110997.html
 

2122 Postings, 3915 Tage macosARO-ANG3

 
  
    
15.05.19 19:23
noch zu 100% im Besitz von ARWR hat Blockbusterpotential? Angriff auf den Statinemarkt von 15 Milliarden Dollar?
Und NASH?


So Wong, Ph.D., Arrowhead?s director of biology, will deliver a poster presentation titled, ?Reduction in Angiopoietin-Like Protein 3 via RNA Interference Improves Dyslipidemias and Hepatic Steatosis?
http://ir.arrowheadpharma.com/static-files/...-44a8-82d3-4424e71482ed
 

2122 Postings, 3915 Tage macoszu ARO-ANG3 und ARO-APOC3 CC vom 8.5.2019

 
  
    
18.05.19 13:26
These are both attractive targets that could address a number of high-value, unmet medical needs, and we are the first to use RNAi against them in humans. They each provide a degree of optionality with respect to which patient populations and indications to study and pursue. For each target, there may be opportunities to treat well-defined orphan diseases such as familial chylomicronemia syndrome and homozygous familial hypercholesterolemia as well as higher prevalence diseases such as NASH or even primary and secondary prevention of cardiovascular disease. We will follow where the data lead us, and dependent on patient populations we choose to focus on, we could have a rapid path to pivotal studies. I expect that we will address clear orphan indications immediately, and I think it is even possible that we could be in pivotal studies for both ARO-APOC3 and ARO-ANG3 next year. We could then begin longer-term studies for larger indications concurrently given us a stage market approach where we move toward orphan markets quickly while we wait for studies of larger indications to mature and eventually go-to-market there as well. Our intention is to discuss our plans for the programs in more detail and describe the potential opportunities and development paths later this year.
Importantly, we believe these targets are well suited for RNAi therapy, and we are the first company to use this modality against them in the clinic. We believe that we can build maximum value for our shareholders by focusing on being pioneers rather than followers, and ARO-APOC3 and ANG3 are good examples of this. More broadly, we intend to be first in our target markets where possible. If instances arise where there is an incumbent, we expect to enter a market only if we believe we have clear technological superiority.
https://finance.yahoo.com/news/...-earnings-conference-075110997.html  

2122 Postings, 3915 Tage macosNational Lipid Association Scientific Sessions

 
  
    
18.05.19 13:29
May 18, 2019 11:25 AM EDT
                    §
2019 National Lipid Association Scientific Sessions


So Wong, Ph.D., Arrowhead?s director of biology, will deliver a poster presentation titled, ?Personalized Medicine for Dyslipidemias by RNA Interference-Mediated Reductions in Apolipoprotein C3 or Angiopoietin-Like Protein 3?
http://ir.arrowheadpharma.com/events-and-presentations

 

2122 Postings, 3915 Tage macosAufnahme in den S&P SmallCap 600

 
  
    
21.05.19 10:55
nachbörslich über 20 Dollar :-)))

Kontoor Brands and Arrowhead Pharmaceuticals Set to Join S&P SmallCap 600
https://finance.yahoo.com/news/...-pharmaceuticals-set-215600185.html  

2122 Postings, 3915 Tage macosMerck to Acquire Peloton Therapeutics

 
  
    
21.05.19 18:17

Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline

Acquisition Includes Novel Late-Stage Renal Cell Carcinoma Candidate, PT2977
ENILWORTH, N.J. & DALLAS--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Peloton Therapeutics, Inc. today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately held Peloton, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2? (HIF-2?) for the treatment of patients with cancer and other non-oncology diseases. Peloton?s lead candidate is PT2977, a novel oral HIF-2? inhibitor in late-stage development for renal cell carcinoma (RCC).

Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Peloton in exchange for an upfront payment of $1.05 billion in cash. In addition, Peloton shareholders will be eligible to receive a further $1.15 billion contingent upon successful achievement of future regulatory and sales milestones for certain candidates.
https://www.businesswire.com/news/home/...olstering-Oncology-Pipeline

ARO-HIF2a soll dieses Jahr noch in die Klinik?
 

2122 Postings, 3915 Tage macosder Cheffe

 
  
    
24.05.19 20:01
sagt wir sind besser als Antikörper oder Antisense?

von der Konferenz  20th Annual B. Riley FBR
http://bioboyscout.com/fbr/  

2122 Postings, 3915 Tage macosbei Twitter gesichtet :-)

 
  
    
1
25.05.19 12:12
 
Angehängte Grafik:
d7wuezbuwaesrqk.jpg (verkleinert auf 66%) vergrößern
d7wuezbuwaesrqk.jpg

2122 Postings, 3915 Tage macoszu 353

 
  
    
25.05.19 14:00
$ARWR will be flying with big pharma in a couple years -- a Bigpharma in the making. Best biotech long op for the next 5 years imo. #winning #beststocktoown #10bagger
https://twitter.com/MookTrader/status/1131973963297333249  

2122 Postings, 3915 Tage macosARO-AAT

 
  
    
25.05.19 23:14
BioBoyScout
? $ARWR ARO-AAT Pivotal Phase 2/3 trial design and dosing schedule all on one chart, as best interpreted, estimated, and compiled by @bioboyscout from known information. Shows pivot point where FDA may allow filing for approval as early as mid 2020. #Genius #RNAi #biotech #GameOn
https://twitter.com/BioBoyScout/status/1131200241305362432  
Angehängte Grafik:
d7ltc6zwkae4efx.png (verkleinert auf 55%) vergrößern
d7ltc6zwkae4efx.png

2122 Postings, 3915 Tage macosmein persönliches Kursziel

 
  
    
25.05.19 23:22
750 Dollar bis Ende 2025 :-)  

16482 Postings, 3356 Tage Balu4u52 Wochen Hoch 24,29 (24.05.2019)

 
  
    
2
27.05.19 19:37
Neues Jahreshoch und Mehrjahreshoch zuletzt mit starkem Volumen!  

2122 Postings, 3915 Tage macosBlackRock hat hinzugefügt

 
  
    
08.06.19 11:44

2122 Postings, 3915 Tage macosnächster JNJ Meilenstein am 17 Juli 2019?

 
  
    
12.06.19 10:42
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
Estimated Study Start Date : July 17, 2019
Estimated Primary Completion Date : January 15, 2021
Estimated Study Completion Date : December 22, 2022
https://clinicaltrials.gov/ct2/show/NCT03982186  

2122 Postings, 3915 Tage macosARO-AAT

 
  
    
12.06.19 10:46
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
Estimated Study Start Date : June 15, 2019
Estimated Primary Completion Date : May 1, 2023
Estimated Study Completion Date : May 1, 2023
https://clinicaltrials.gov/ct2/show/NCT03945292?cond=AAT&rank=4  

2122 Postings, 3915 Tage macos19 Mille short bei 95,5 ausstehend

 
  
    
12.06.19 10:52
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
   5/31/2019               19,147,477                   5,125,073               3.736040
https://www.nasdaq.com/symbol/arwr/short-interest  

2122 Postings, 3915 Tage macosDD

 
  
    
12.06.19 11:00
BioBoyScout's Proprietary Due Diligence, Analysis,
and Opinion on Arrowhead Pharmaceuticals, Inc.
http://bioboyscout.com/xxx/  

Seite: Zurück 1 | 2 | 3 | 4 |
13 | 14 | 15 | 15  Weiter  
   Antwort einfügen - nach oben